**Allersearch®
ADS™ has been administered to asthmatic and normal subjects
via a nebulizer to determine whether it could provoke bronchospasm.
No effect on FEV1 was observed. No changes in expiratory flow rate
were observed when asthmatics, whose homes were sprayed with Allersearch®
were tested. Allersearch® ADS™ meets the current requirements
of State Health Departments and other government authorities. Adverse
affects have been rare. These reports have been limited to a contact
dermatitis. Patients are advised not to reduce asthma medication
(particularly steroids) without medical advice.
|
